« Previous
Next »
Gastroenterology
Volume 141, Issue 4
, Pages 1194-1201
, October 2011
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
To access this article, please choose from the options below
Conflicts of interest Paul Rutgeerts, William Sandborn, Jean Frédéric Colombel, Stephen Hanauer, Gary Lichtenstein, Walter Reinisch, Bruce Sands, and Brian Feagan have served as consultants for Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC and Schering–Plough, a subsidiary of Merck & Co, Inc; Paul Rutgeerts, William Sandborn, Stephen Hanauer, Bruce Sands, Brian Feagan, Walter Reinisch, and Gary Lichtenstein have participated in continuing medical education events supported by unrestricted educational grants from Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC and Schering Corporation, a subsidiary of Merck & Co, Inc; Björn Oddens and Yanxin Wang are employees of Schering Corporation, a subsidiary of Merck & Co, Inc; Colleen Marano and Richard Strauss are employees of the Department of Immunology, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, and Yinghua Lang is an employee of the Department of Biostatistics, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC; and Dirk Esser is a former employee of Janssen Biologics BV and is currently an employee of Boerhringer–Ingelheim.
Funding Supported by a research grant from Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC (Malvern, PA) and Schering Corporation, a subsidiary of Merck & Co, Inc (Kenilworth, NJ); this study was designed and conducted by the ACT-1 and ACT-2 Steering Committees, Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC and Schering Corporation (a subsidiary of Merck & Co, Inc) who jointly analyzed and interpreted the data, and contributed to the manuscript; Drs Colombel, Rutgeerts, and Sandborn prepared the first draft of the manuscript, and the ACT-1 and ACT-2 Steering Committee made the decision to publish; editorial and writing support was provided by James P. Barrett, an employee of the Medical Affairs Publications Group, Janssen Services, LLC.
PII: S0016-5085(11)00904-8
doi: 10.1053/j.gastro.2011.06.054
© 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Gastroenterology
Volume 141, Issue 4
, Pages 1194-1201
, October 2011

